Summary
The product Cypilos 250 mg/ml, manufactured by DriadaMedical, was analyzed to verify its composition and potency. The sample, identified by batch number 669938, was tested by Janoshik Analytical, a laboratory known for its expertise in pharmaceutical quality testing. The analysis confirmed the presence of Testosterone Cypionate with a measured concentration of 228.43 mg/ml, reflecting an 8.63% variance below the label claim. The product was retested twice to ensure accuracy. These findings suggest that the product is slightly underdosed but remains within an acceptable margin of accuracy.
The testing process was initiated on 6 January 2022, with the sample received on 7 January 2022, and the analysis completed on 9 January 2022. As the sample was submitted and paid for by the manufacturer, DriadaMedical, the results warrant careful scrutiny. This report serves an educational purpose, aiming to help consumers make informed decisions about the accuracy and consistency of anabolic steroid products.
Detailed Report
Product Overview
- Manufacturer: DriadaMedical
- Product Name: Cypilos 250 mg/ml
- Active Ingredient: Testosterone Cypionate
- Batch Number: 669938
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #16176
- Testing Ordered: 6 January 2022
- Sample Received: 7 January 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: DriadaMedical (Manufacturer)
- Analysis Paid For By: DriadaMedical (Manufacturer)
Testing Results
- Specification: 250 mg/ml (as stated on the label)
- Measured Concentration: 228.43 mg/ml
- Accuracy: 91.37% (8.63% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/16176_Q1ZNLCWL4NVQ
- Originally Published: https://thinksteroids.com/community/threads/driada-medical-finished-products-lab-tests-results.134426425/
Evaluation of Manufacturer-Funded Testing
This test report was both submitted and funded by the manufacturer, DriadaMedical, which necessitates a critical evaluation of the findings. Manufacturer-funded testing may involve selective sample submission or implicit pressure on the laboratory. However, the credibility of Janoshik Analytical, along with its history of transparency and reliable analysis, adds confidence to the results. Cross-referencing with third-party testing, when available, is recommended to further substantiate the findings.
Conclusion
The analysis demonstrates that Cypilos 250 mg/ml from DriadaMedical is slightly underdosed compared to its labeled specification, with a measured concentration of 228.43 mg/ml. This report offers valuable insights for educational and harm reduction purposes, encouraging informed decision-making among consumers. Independent validation would further strengthen the confidence in these results.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
